[
  {
    "ts": null,
    "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
    "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
    "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917800,
      "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
      "id": 136295231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
      "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703"
    }
  },
  {
    "ts": null,
    "headline": "Biogen, Stoke Therapeutics Dose First Patient in Phase 3 Trial of Zorevunersen for Dravet Syndrome",
    "summary": "Biogen (BIIB) and Stoke Therapeutics (STOK) said Monday they have dosed a first participant in a pha",
    "url": "https://finnhub.io/api/news?id=534337382586b46f9ea2f8c1c5acc29450adc535e42615067428c75ff2a6bf7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754915050,
      "headline": "Biogen, Stoke Therapeutics Dose First Patient in Phase 3 Trial of Zorevunersen for Dravet Syndrome",
      "id": 136295263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) and Stoke Therapeutics (STOK) said Monday they have dosed a first participant in a pha",
      "url": "https://finnhub.io/api/news?id=534337382586b46f9ea2f8c1c5acc29450adc535e42615067428c75ff2a6bf7e"
    }
  },
  {
    "ts": null,
    "headline": "Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome",
    "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., August 11, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifyin",
    "url": "https://finnhub.io/api/news?id=afa82ba6bb4a5a3fbde9fb43fa9238cb6aef88050ffbdb8728ac0e7b55298cc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754910000,
      "headline": "Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome",
      "id": 136295265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., August 11, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifyin",
      "url": "https://finnhub.io/api/news?id=afa82ba6bb4a5a3fbde9fb43fa9238cb6aef88050ffbdb8728ac0e7b55298cc0"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome",
    "summary": "– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that address the underlying cause of the disease – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology com",
    "url": "https://finnhub.io/api/news?id=f4302736e134d312db861ee6a42413e3c15b1a6f3c006c01855f4df08bd69d95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754910000,
      "headline": "Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome",
      "id": 136295264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that address the underlying cause of the disease – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology com",
      "url": "https://finnhub.io/api/news?id=f4302736e134d312db861ee6a42413e3c15b1a6f3c006c01855f4df08bd69d95"
    }
  },
  {
    "ts": null,
    "headline": "Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035",
    "summary": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakness and sensory issues. Often considered the chronic counterpart to Guillain-Barré syndrome, CIDP progresses slowly and can be recurrent. The global CIDP market is growing due to increased awareness, improved diagnostics, and demand for advanced treatments, including targeted biologic therapies like FcRn inhibitors. However, challenges such as high t",
    "url": "https://finnhub.io/api/news?id=59d34aff570a51957d49ab370795dd4b8774689358da1f42bfc8b9809a1923ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754905680,
      "headline": "Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035",
      "id": 136292708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakness and sensory issues. Often considered the chronic counterpart to Guillain-Barré syndrome, CIDP progresses slowly and can be recurrent. The global CIDP market is growing due to increased awareness, improved diagnostics, and demand for advanced treatments, including targeted biologic therapies like FcRn inhibitors. However, challenges such as high t",
      "url": "https://finnhub.io/api/news?id=59d34aff570a51957d49ab370795dd4b8774689358da1f42bfc8b9809a1923ba"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136294362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136292433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d"
    }
  }
]